Trv Gp Iii, LLC Nurix Therapeutics, Inc. Transaction History

Trv Gp Iii, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$12.94 - $29.65 $6.47 Million - $14.8 Million	-500,000 Reduced 20.64%	1,922,549 $26.9 Million
Q3 2021 Nov 05, 2021	SELL	$22.71 - $36.69 $22.7 Million - $36.7 Million	-1,000,000 Reduced 29.22%	2,422,549 $72.6 Million
Q2 2021 Aug 11, 2021	SELL	$24.21 - $35.89 $26.3 Million - $39 Million	-1,085,784 Reduced 24.08%	3,422,549 $90.8 Million
Q1 2021 May 12, 2021	SELL	$26.98 - $50.17 $24.7 Million - $45.9 Million	-914,216 Reduced 16.86%	4,508,333 $140 Million
Q3 2020 Nov 06, 2020	BUY	$16.05 - $34.91 $87 Million - $189 Million	5,422,549 New	5,422,549 $189 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Trv Gp Iii, LLC, based on Form 13F filings with the SEC.

Stay updated on Trv Gp Iii, LLC with notifications on news.